Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite — which was longer than usual on this side of the pond due to a federal holiday — was relaxing and refreshing, because that oh-so-familiar routine of meetings, deadlines, and the like has, predictably, returned. To cope, yes, we are quaffing cups of stimulation, especially since the arctic tundra has come to town. Perhaps you can relate? In any event, here are some tidbits to warm your engines. Hope today is smashing and, as always, do keep in touch …

GlaxoSmithKline (GSK) chairman Philip Hampton, 65, will step down after just four years in the role, The Evening Standard notes. No date was given for when he will leave, but the hunt for a successor has begun. The disclosure comes a month after drug maker unveiled a deal with Pfizer (PFE) to create a consumer-health powerhouse, a move that will leave Glaxo with a standalone pharmaceuticals business, which chief executive Emma Walmsley is keen to strengthen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.